We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CTO Tclarke Plc

1.00 (0.62%)
Last Updated: 15:23:35
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tclarke Plc LSE:CTO London Ordinary Share GB0002015021 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.00 0.62% 161.00 161.00 161.50 162.00 161.00 161.00 98,364 15:23:35
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Special Trade Contractor,nec 491M 6.5M 0.1230 13.09 85.09M
Tclarke Plc is listed in the Special Trade Contractor sector of the London Stock Exchange with ticker CTO. The last closing price for Tclarke was 160p. Over the last year, Tclarke shares have traded in a share price range of 105.00p to 162.00p.

Tclarke currently has 52,850,780 shares in issue. The market capitalisation of Tclarke is £85.09 million. Tclarke has a price to earnings ratio (PE ratio) of 13.09.

Tclarke Share Discussion Threads

Showing 5076 to 5098 of 5100 messages
Chat Pages: 204  203  202  201  200  199  198  197  196  195  194  193  Older
CTO ramping up the news flow this week. Let's hope it helps bring in more bidders....

Prestigious London contract win:

TClarke Healthcare tech in 80% + of all new UK scanning facilities:

Now up to 2% and share price above offer price, so have they bought some more this morning? A number of sells at just above the offer price.
I assume they are not there just to collect the 4.5p dividend......
Someone bought 1.7%??
well i first bought these in 2013 ..... at 62p, but very disappointed at todays price. bit of a rollercoaster ride but plenty of dividends on the way. A very sad day
Salpara, your moaning about a price of £1.60 for a takeover, but you and lots of others weren't interested in buying these in the mid 120s. 🤷
Well I sold out last week after 2 years of underperformance. Impeccable timing. Seemed to be a vanity project with high turnover, low profits and fat director salaries. Much to my annoyance its seems another company sees value where I didn't
dr biotech
Watched this for some time but never took a stake.
I am amazed that the BOD are recommending this really poor premium when the share price was near a multi year low. The only conclusion one can reach is that current/forward prospects are not anywhere near as positive as the market has been led to believe.

Not entirely the fault of pension funds after Gordon Brown's raid on dividends...

Got to agree this is a poor price. Wincanton went for a fantastic premium after a second bid came along... so maybe worth sticking around?

Pension funds are to blame, uk Pension funds only invest 4% in there home market. Whilst overseas Pension funds invest 20% on average in there home market..
This country has been a financial disaster since Brexit, Covid didn't help but either. Interestingly the people who moan about companies being bought out on the cheap - because there seems to be no investor appetite - are the ones who voted for it. Suck it up.
Another one gone. Lots of research, numbers look good and then cannot understand why the price stays low. Then gets bought out cheap. There will be no companies left in the UK. Makes you think this is what the people in charge of the UK want.
I agree this is a very poor bid. T Clarke were trading at well above 160 in 2022 and only last month the directors were saying how bright the future was! I think they are worth over £2.
not impressed ... seems to be a sign of the poor UK market
Bad news for me as its one of three companies I hold outside a ISA or Sipp wrapper. And allowance is only 3k now..
Really disappointing price - not quite sure how Cavendish can have advised the Board to recommend it at that low valuation. Difficult, but not impossible to see a competing bidder arise.
So Regent are to acquire CTO for just over 164.5p. A good result for me investment-wise, but a very poor one in terms of CTO's worth, and taking advantage of the one-off dip following the very unusual contract difficulties last year.

Regent have 21%, so 24% including the directors' shares. Maybe not enough to win through if there's significant opposition or to defeat a rival bidder?

Yet another example of listed UK companies being extremely undervalued, especially a top quality company like CTO given its increasing exposure to data centres, healthcare, ESG and the like.

News - interesting to see CTO growing and getting trade approval for an "in-house panel manufacturing division that builds control panels for medical imaging equipment OEMs such as Siemens Healthcare, GE Healthcare, Philips Healthcare, Canon and many more":
At least somewhat aligned with shareholders EPS / TSR measures.Let's hope the directors make a lot of money because we will too....
Jeez, have these guys NO shame??
FYI here's Cavendish's summary from their new research note, forecasting 24.1p EPS this year, with a 6.5p dividend and £16.6m net cash:

"High quality projects across a range of sectors

TClarke’s FY 2023 results and forward-looking commentary are in line with the November trading statement, and we make no changes to our forecasts. Revenue of £491m in 2023 exceeded the 3-year plan to double revenue from £232m in 2020 and management have confirmed the group is well positioned to achieve growth plans for 2024 and beyond backed by the £943m order book (up +70%). FY 2023 PBT of £7.6m is down from £10.3m in 2022 due to the previously highlighted measures to protect the business from the current, very challenging construction market conditions. These measures included changing some supply-chain partners mid-contract to protect project completion dates, and the early finalisation of project accounts where customer risk had been identified. All projects are expected to be delivered according to their schedules but the one-off costs of these measures restricted the operating margin to 1.9%, below the target 3.0% (2022: 2.7%, 2024E 3.1%).

We reiterate our view that on a 2024E P/E of 5.3x (vs peers 9.1x who are subject to the same market challenges), dividend yield of 5.1% and net cash of £19m the valuation underestimates the company’s long-term growth potential, and market and financial position. The key driver for the share price will be increasing evidence as the year progresses of forecast deliverability.

- Order book up 70%. The strategy of organic growth focused on five core market sectors whilst building market presence in data centres, large projects outside of London, smart buildings and healthcare is delivering. Data centres now account for £346m within the total £943m order book. This total compares to £1.1bn at October 2023 due to the normal seasonally lower win rate at the end of the year being offset by orders completed (H2 revenue was up +37% on H1).

- Net cash £19.3m up from £7.5m. Key movements were: equity raised £10.1m, dividend cost £2.5m, and free cash flow £4.1m. Importantly, given the market conditions, bad debt expense was only £0.3m and in line with the group’s historical average. On the balance sheet contract assets increased by £30m as one of the large, multi-year contracts ramped-up activity, offset by a £30m increase in trade creditors reflecting the strong cash characteristics of this contract.

- Dividend raised 10% as expected. The 2023 dividend was raised to 5.9p from 5.35p reflecting the progressive dividend policy, net cash and growth prospects.

- Medium-term target price 197p, +55% upside. Our medium-term target price is based on a -10% discount to the broad peer group average 2024E P/E. The discount reflects the impact of the larger, highly rated renewals and infrastructure operators within peers. We do not expect construction market conditions to significantly improve in the short term and expect the share price to be driven by increasing confidence in TClarke’s revenue, margin and cash flow forecasts as the year progresses"

20:54 Andrew Gibb and Guy Hewett at Cavendish Capital Markets estimate that the year to end December 2024 will see £600m revenues, with adjusted pre-tax profits rebounding to £17.1m, hoisting earnings up to 24.1p and amply covering a 6.5p dividend per share.For 2025 they see £650m, £19.1m, 26.9p and 7.1p respectively.Those estimates easily back up the analyst's Medium-Term Price Objective of 197p for the group's shares.At the end of last week, the shares, which hit 159p last June, were fractionally lower at 122.50p – at which level they are a strong hold for existing shareholders and offer a bargain for newcomers.
I agree. Looked at this several times but the board remuneration is beyond outrageous.
Chat Pages: 204  203  202  201  200  199  198  197  196  195  194  193  Older

Your Recent History

Delayed Upgrade Clock